Information Provided By:
Fly News Breaks for November 11, 2019
FGEN
Nov 11, 2019 | 06:44 EDT
Mizuho analyst Difei Yang raised her price target for FibroGen to $72 from $65 after the company reported MACE data from the global Phase 3 clinical trials of roxadustat. The data were positive with non-inferiority to placebo in the non dialysis-dependent setting and non-inferiority versus standard of care erythropoiesis stimulating agents in the dialysis-dependent setting, Yang tells investors in a research note. She believes the "path to approval is clear" and reiterates a Buy rating on FibroGen.
News For FGEN From the Last 2 Days
There are no results for your query FGEN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.